Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor - Related apoptosis-inducing ligand receptor 2

Clinical Cancer Research

Volumn 11, Issue 8, 2005, Pages 3126-3135

  Motoki, Kazuhiro ^a   Mori, Eiji ^a   Matsumoto, Atsushi ^a   Thomas, Mayumi ^a   Tomura, Takafumi ^a   Humphreys, Robin ^b   Albert, Vivian ^b   Muto, Mari ^a   Yoshida, Hitoshi ^a   Aoki, Masami ^a   Tamada, Taro ^a   Kuroki, Ryota ^a   Yoshida, Hideaki ^a   Ishida, Isao ^a   Ware, Carl F ^c   Kataoka, Shiro ^a  

^a KIRIN BREWERY CO LTD   (Japan)

^b GLAXOSMITHKLINE   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR AGONIST; DEATH RECEPTOR 5; FC RECEPTOR; IMMUNOGLOBULIN G; KMTR2 ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTICLE; COLORECTAL CARCINOMA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS LINKING; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; EFFECTOR CELL; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNIZATION; IN VIVO STUDY; MEMBRANE BINDING; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20244378961     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1867     Document Type: Article

References (37)

1. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
2. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003;14:337-48.
3. Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 2002;7:449-59.
4. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501.
5. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
6. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
7. Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31-8.
8. Evdokiou A, Bouralexis S, Atkins GJ, et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002;99:491-504.
9. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-5.
10. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954-60.
11. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
12. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for thecytotoxic ligand TRAIL. Science 1997;276:111-3.
13. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-97.
14. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 1997;7:821-30.
15. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997;7:693-6.
16. Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165-70.
17. Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997;7:1003-6.
18. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-7.
19. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21.
20. Pan G, Ni J, Wei Y-F, Yu G-L, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-7.
21. Griffith TS, Rauch CT, Smolak PJ, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999;162:2597-605.
22. Chuntharapai A, Dodge K, Grimmer K, et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001;166:4891-8.
23. Xu Y, Szalai AJ, Zhou T, et al. FcγRs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol 2003;171:562-8.
24. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 2002;62:5813-7.
25. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754-8.
26. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
27. Mori E, Thomas M, Motoki K, et al. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 2004;11:203-7.
28. Ishida I, Tomizuka K, Yoshida H, et al. Production of human monoclonal and polyclonal antibodies in Trans-Chromo animals. Cloning Stem Cells 2002;4:91-102.
29. Kamishohara M, Kawai H, Sakai T, et al. Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells. Oncol Res 1994;6:383-90.
30. Fahrner RL, Knudsen HL, Basey CD, et al. Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev 2001;18:301-27.
31. Francisco JA, Donaldson KL, Chace D, Siegall CB, Wahl AF. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14. Cancer Res 2000;60:3225-31.
32. Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci U S A 1997;94:7509-14.
33. Miller K, Meng G, Liu J, et al. Design, construction, and in vitro analyses of multivalent antibodies. J Immunol 2003;170:4854-61.
34. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000;288:2351-4.
35. Hueber AO, Bernard AM, Herincs Z, Couzinet A, He HT. An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep 2002;3:190-6.
36. Semac I, Palomba C, Kulangara K, et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 2003;63:534-40.
37. Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation. Immunity 2003;18:655-64.